In neurofibromatosis type 2 (NF2), SRS offers durable tumor control, though hearing preservation and clinical outcomes varies as it contingent on the complex clinical presentation and disease burden, a unique challenge of NF2 patients. Here, NF2 is linked to NF2-related schwannomatosis.